Scholars@Duke
James Bernard Hermiller Jr.

James Bernard Hermiller Jr.

Adjunct Assistant Professor in the Department of Medicine
Medicine, Cardiology
Duke Box 3845, Durham, NC 27710
7451 Hospital North, Durham, NC

Scholarly Works

Abbreviated DAPT Regimens Across the Entire Spectrum of Bleeding Risk According to the PRECISE-HBR Score

Journal article Jacc Cardiovascular Interventions · July 13, 2026 Background Among high–bleeding risk (HBR) patients undergoing coronary stenting, abbreviated dual antiplatelet therapy (DAPT) reduces bleeding without ischemic risk trade-off; whether these benefits persist across the entire spectrum of bleeding risk has n ... Full text Cite

Impact of Adverse Events on Costs and Length of Stay Following Transcatheter Tricuspid Valve Replacement.

Journal article Struct Heart · July 2026 BACKGROUND: Transcatheter tricuspid valve replacement (TTVR) with the EVOQUE system has emerged as an effective therapy for severe tricuspid regurgitation. The costs and resource utilization associated with TTVR, particularly in the context of major advers ... Full text Link to item Cite

Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.

Journal article J Am Coll Cardiol · June 16, 2026 BACKGROUND: The Evolut Low Risk trial enrolled patients with severe aortic stenosis at low surgical risk. Annual follow-up is planned for 10 years, evaluating the composite of all-cause mortality or disabling stroke and key secondary endpoints. OBJECTIVES: ... Full text Link to item Cite

ALARA+: Summit on Radiation and Orthopedic Risks in Fluoroscopic Laboratories.

Journal article Heart Rhythm · June 2026 Occupational radiation exposure has a clear association with long-term health effects and has a particular impact on women, trainees, and supporting staff. There is a reliance on limited, traditional radiation protection and nonergonomic equipment, which c ... Full text Link to item Cite

ALARA+: Summit on Radiation and Orthopedic Risks in Fluoroscopic Laboratories: Endorsed by ACC, ACVP, ASE, HRS, SCAI, SIR, SNIS, SVIN, and SVS.

Journal article J Vasc Interv Radiol · June 2026 Occupational radiation exposure has a clear association with long-term health effects and has a particular impact on women, trainees, and supporting staff. There is a reliance on limited, traditional radiation protection and nonergonomic equipment, which c ... Full text Link to item Cite

Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial.

Journal article Eur Heart J · May 5, 2026 BACKGROUND AND AIMS: The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therap ... Full text Link to item Cite

Impact of a Novel Radiation Protection System on Door-to-Balloon Time During STEMI Intervention.

Journal article J Soc Cardiovasc Angiogr Interv · February 2026 BACKGROUND: Prolonged radiation exposure remains a critical occupational hazard in the catheterization lab, typically mitigated by lead aprons, which contribute to orthopedic injury. Recent innovations like the Rampart M1128 enhanced radiation protection s ... Full text Link to item Cite

Benefit of coronary stenting using available intracoronary tools in high-risk patients. The OPTI-XIENCE study.

Journal article Int J Cardiol · January 1, 2026 BACKGROUND: The clinical benefit of using ICT for coronary stent optimization remains uncertain in randomized trials, in which a unique ICT was used in most cases. AIM: To assess the clinical impact of intracoronary techniques (ICT) for stent optimization ... Full text Link to item Cite

ALARA+: Summit on Radiation and Orthopedic Risks in Fluoroscopic Laboratories

Journal article Jvs Vascular Insights · January 1, 2026 Occupational radiation exposure has a clear association with long-term health effects and has a particular impact on women, trainees, and supporting staff. There is a reliance on limited, traditional radiation protection and nonergonomic equipment, which c ... Full text Cite

Optimizing Radiation Safety Without Compromising Quality of Care.

Journal article JACC Case Rep · November 12, 2025 BACKGROUND: Cumulative radiation exposure in the cardiac catheterization laboratory poses substantial long-term health risks to operators and staff. Although lead aprons mitigate exposure, they contribute to occupational injury. Recent innovations such as ... Full text Link to item Cite

CLASP IID Trial and Registry: 2-Year Outcomes of Transcatheter Repair for Degenerative Mitral Regurgitation.

Journal article JACC Cardiovasc Interv · October 13, 2025 BACKGROUND: One-year outcomes from the CLASP IID Trial (Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial; NCT03706833) and Registry established the PASCAL transcatheter valve repair system as a safe and effective treatment for prohib ... Full text Link to item Cite

The need for future coronary access in older medicare beneficiaries following transcatheter aortic-valve replacement.

Journal article Cardiovasc Interv Ther · October 2025 BACKGROUND: While approximately 17% of patients less than 80 years old require coronary access in the 7 years following their TAVR, the need for coronary access among older TAVR patients is unknown. METHODS: We examined the percentage of Medicare beneficia ... Full text Link to item Cite

One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme.

Journal article EuroIntervention · June 16, 2025 BACKGROUND: In patients with diabetes mellitus (DM) and high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI), the optimal duration of dual antiplatelet therapy (DAPT) remains uncertain. AIMS: We sought to compare early DAPT disconti ... Full text Link to item Cite

Real-World Reductions in Lead-Free Radiation Exposure with the Rampart System during Endovascular Procedures.

Journal article Am J Cardiol · May 15, 2025 Endovascular operators experience elevated rates of occupational orthopedic injuries and persistent radiation exposure with current lead shielding. Novel shielding systems eliminate the need to wear lead aprons while also mitigating occupational radiation ... Full text Link to item Cite

Occupational Health Hazards in the Cardiac Catheterization Laboratory: Results of the 2023 SCAI Survey.

Journal article J Soc Cardiovasc Angiogr Interv · April 2025 BACKGROUND: The demands and hazards of working in the cardiac catheterization laboratory (CCL) are well-represented in the literature and include radiation exposure, orthopedic injuries, and physical and psychological stress. This analysis aimed to compare ... Full text Link to item Cite

5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial.

Journal article J Am Coll Cardiol · March 25, 2025 BACKGROUND: The Amulet IDE trial (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial) evaluated the safety and effectiveness of the Amulet occluder (Abbott) in patients with nonvalvular atrial fibrillation. ... Full text Link to item Cite

Posterior Leaflet Mitral Valve Repair with Septal Myectomy For Hypertrophic Cardiomyopathy

Journal article Operative Techniques in Thoracic and Cardiovascular Surgery · March 1, 2025 Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, and presents with left ventricular hypertrophy resulting in left ventricular outflow tract (LVOT) obstruction in 60% of patients. Standard surgical therapy for the relief of out ... Full text Cite

Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention.

Journal article Circulation · February 11, 2025 BACKGROUND: Accurate bleeding risk stratification after percutaneous coronary intervention is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of patients at high bleeding r ... Full text Link to item Cite

Timing and Outcomes of PCI in Conjunction With TAVR With Balloon-Expandable Valves.

Journal article JACC Cardiovasc Interv · January 27, 2025 BACKGROUND: The optimal timing for percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve replacement (TAVR) is debatable. OBJECTIVES: The aim of this study was to compare outcomes based on the timing of PCI in stable co ... Full text Link to item Cite

One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.

Journal article EuroIntervention · May 20, 2024 BACKGROUND: A short dual antiplatelet therapy (DAPT) duration has been proposed for patients at high bleeding risk (HBR) undergoing drug-eluting coronary stent (DES) implantation. Whether this strategy is safe and effective after a non-ST-segment elevation ... Full text Link to item Cite

Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results.

Journal article Eur J Heart Fail · April 2024 AIMS: Patients with heart failure and mildly reduced or preserved ejection fraction have limited therapeutic options. The ALT-FLOW Early Feasibility Study evaluated safety, haemodynamics and outcomes for the APTURE transcatheter shunt system, a novel left ... Full text Link to item Cite

1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program.

Journal article Am J Cardiol · March 1, 2024 This analysis aimed to evaluate the effect of 1- versus 3-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in older patients. Data from 3 prospective, single-arm studies (XIENCE Short DAPT Program), including patients w ... Full text Link to item Cite

Breaking Down Barriers to Transcatheter Aortic Valve Replacement.

Journal article J Soc Cardiovasc Angiogr Interv · March 2024 Full text Link to item Cite

1-Year Outcomes of Transcatheter Edge-to-Edge Repair in Anatomically Complex Degenerative Mitral Regurgitation Patients.

Journal article JACC Cardiovasc Interv · December 11, 2023 BACKGROUND: Favorable 6-month outcomes from the CLASP IID Registry (Edwards PASCAL transcatheter valve repair system pivotal clinical trial) demonstrated that mitral valve transcatheter edge-to-edge repair with the PASCAL transcatheter valve repair system ... Full text Link to item Cite

Salvaging a Disaster: “Threading the Wrong Needle”

Journal article Journal of the Society for Cardiovascular Angiography and Interventions · November 1, 2023 Full text Cite

One-Year Outcomes From the CLASP IID Randomized Trial for Degenerative Mitral Regurgitation.

Journal article JACC Cardiovasc Interv · October 26, 2023 BACKGROUND: The CLASP IID (Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical) trial is the first randomized controlled trial comparing the PASCAL system and the MitraClip system in prohibitive risk patients with significant symptomatic dege ... Full text Link to item Cite

1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI.

Journal article JACC Cardiovasc Interv · October 23, 2023 BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients on long-term oral anticoagulation (OAC) therapy is still uncertain. OBJECTIVES: The aim of this analysis was to assess the effec ... Full text Link to item Cite

Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study.

Journal article J Am Coll Cardiol · September 26, 2023 BACKGROUND: Real-world applicability of the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) randomized controlled trial (RCT) has been debated because of caref ... Full text Link to item Cite

3-Year Outcomes From the Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE).

Journal article JACC Cardiovasc Interv · August 14, 2023 BACKGROUND: The Amulet (Abbott) left atrial appendage occluder investigational device exemption trial is the largest randomized trial evaluating the safety and effectiveness of the Amulet left atrial appendage occluder compared with the Watchman 2.5 device ... Full text Link to item Cite

Left Atrial to Coronary Sinus Shunting for Treatment of Symptomatic Heart Failure.

Journal article JACC Cardiovasc Interv · June 12, 2023 BACKGROUND: Heart failure (HF) is associated with both mortality and a significant decline in health status. Interatrial shunting is increasingly being investigated as a novel therapeutic option. OBJECTIVES: The ALT FLOW Early Feasibility Study was designe ... Full text Link to item Cite

1-Year Outcomes of Transcatheter Tricuspid Valve Repair.

Journal article J Am Coll Cardiol · May 9, 2023 BACKGROUND: Surgical management of isolated tricuspid regurgitation (TR) is associated with high morbidity and mortality, thereby creating a significant need for a lower-risk transcatheter solution. OBJECTIVES: The single-arm, multicenter, prospective CLAS ... Full text Link to item Cite

Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial.

Journal article J Am Heart Assoc · February 21, 2023 Background The current standard of care for the treatment of patients with primary mitral regurgitation (MR) is surgical mitral valve repair. Transcatheter edge-to-edge repair with the MitraClip device provides a less invasive treatment option for patients ... Full text Link to item Cite

Transcatheter Edge-to-Edge Repair in Patients With Anatomically Complex Degenerative Mitral Regurgitation.

Journal article J Am Coll Cardiol · February 7, 2023 BACKGROUND: Mitral valve transcatheter edge-to-edge repair is safe and effective in treating degenerative mitral regurgitation (DMR) patients at prohibitive surgical risk, but outcomes in complex mitral valve anatomy patients vary. OBJECTIVES: The PASCAL I ... Full text Link to item Cite

Comparison of American and European Guidelines for the Management of Patients With Valvular Heart Disease.

Journal article Cardiovasc Revasc Med · February 2023 This review compares the recommendations of the recent 2020 American College of Cardiology (ACC)/American Heart Association (AHA) and 2021 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines on the manag ... Full text Link to item Cite

Randomized Comparison of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients.

Journal article JACC Cardiovasc Interv · December 26, 2022 BACKGROUND: Severe symptomatic degenerative mitral regurgitation (DMR) has a poor prognosis in the absence of treatment, and new transcatheter options are emerging. OBJECTIVES: The CLASP IID (Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinica ... Full text Link to item Cite

Outcomes of the roll-in cohort of the Amulet IDE trial of left atrial appendage occlusion

Journal article Heart Rhythm O2 · October 1, 2022 Background: Left atrial appendage (LAA) occlusion is an alternative therapy to oral anticoagulants to reduce stroke risk in patients with nonvalvular atrial fibrillation (NVAF). The Amulet IDE trial compared the Amplatzer™ Amulet™ occluder (Abbott) with th ... Full text Cite

Transcarotid versus transthoracic access for transcatheter aortic valve replacement: A propensity-matched analysis.

Journal article J Thorac Cardiovasc Surg · August 2022 OBJECTIVE: Transcarotid access for transcatheter aortic valve replacement is emerging as an alternative to more traditional nonfemoral access options such as transapical or transaortic; however, comparative data are limited. The purpose of the study was to ... Full text Link to item Cite

Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.

Journal article J Am Coll Cardiol · November 23, 2021 BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown. OBJECTIVES: The purpose of this analysis was to compare 1 vs 3 months of DAPT in HBR ... Full text Link to item Cite

Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents.

Journal article Catheter Cardiovasc Interv · November 15, 2021 OBJECTIVE: To investigate the impact of ischemic and bleeding risk factors on long-term clinical outcomes of patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) with everolimus-eluting stents. BACKGROUND: Second-generat ... Full text Link to item Cite

Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.

Journal article Circulation · November 9, 2021 BACKGROUND: Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic oral anticoagulation to reduce stroke risk in patients with nonvalvular atrial fibrillation. The Amulet IDE trial (Amplatzer Amulet Left Atrial Appendage Occlu ... Full text Link to item Cite

The need for future coronary access following surgical or transcatheter aortic valve replacement.

Journal article Catheter Cardiovasc Interv · November 1, 2021 The aim of the study was to estimate the percentage of Medicare patients needing coronary access for percutaneous coronary intervention (PCI) or coronary angiography following aortic valve replacement (AVR). Indications for TAVR have expanded to include yo ... Full text Link to item Cite

Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank.

Journal article Catheter Cardiovasc Interv · November 1, 2021 The Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community annually for h ... Full text Link to item Cite

Early outcomes from the CLASP IID trial roll-in cohort for prohibitive risk patients with degenerative mitral regurgitation.

Journal article Catheter Cardiovasc Interv · October 2021 OBJECTIVES: We report the 30-day outcomes from the roll-in cohort of the CLASP IID trial, representing the first procedures performed by each site. BACKGROUND: The currently enrolling CLASP IID/IIF pivotal trial is a multicenter, prospective, randomized tr ... Full text Link to item Cite

3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.

Journal article JACC Cardiovasc Interv · September 13, 2021 OBJECTIVES: The aim of this study was to evaluate 2 abbreviated dual-antiplatelet therapy (DAPT) regimens in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). BACKGROUND: Current-generation drug-eluting stents are pr ... Full text Link to item Cite

Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies.

Journal article J Thromb Thrombolysis · August 2021 Data on ischemic and bleeding outcomes after percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with chronic kidney disease (CKD) are scarce. We aimed to evaluate the association between CKD and ischemic and bleeding outcomes in ... Full text Link to item Cite

Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial.

Journal article Circ Cardiovasc Interv · June 2021 BACKGROUND: Older adults with comorbidities who are at extreme risk for surgical aortic valve replacement may be appropriate candidates for transcatheter aortic valve replacement (TAVR). We present the 5-year clinical, echocardiographic, and health status ... Full text Link to item Cite

Impact of Coronary Artery Tortuosity on Outcomes Following Stenting: A Pooled Analysis From 6 Trials.

Journal article JACC Cardiovasc Interv · May 10, 2021 OBJECTIVES: The authors sought to determine whether coronary artery tortuosity negatively affects clinical outcomes after stent implantation. BACKGROUND: Coronary artery tortuosity is a common angiographic finding and has been associated with increased rat ... Full text Link to item Cite

Valve-in-Surgical-Valve With SAPIEN 3 for Transcatheter Aortic Valve Replacement Based on Society of Thoracic Surgeons Predicted Risk of Mortality.

Journal article Circ Cardiovasc Interv · May 2021 BACKGROUND: The use of valve-in-valve–transcatheter aortic valve replacement (VIV-TAVR) in degenerated aortic bioprosthesis has been increasing, but the Food and Drug Administration approval is limited to high-risk patients. We analyzed the real-world expe ... Full text Link to item Cite

Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.

Journal article Am Heart J · January 2021 Dual antiplatelet therapy (DAPT) is key for the prevention of recurrent ischemic events after percutaneous coronary intervention (PCI); however, it increases the risk of bleeding complications. While new generation drug-eluting stents have been shown super ... Full text Link to item Cite

Transcarotid Versus Subclavian/Axillary Access for Transcatheter Aortic Valve Replacement With SAPIEN 3.

Conference Ann Thorac Surg · December 2020 BACKGROUND: Subclavian/axillary (TAx) access has become the most frequently used alternative access route for transcatheter aortic valve replacement (TAVR). Transcarotid (TC) TAVR has grown in popularity recently. Comparative data between these 2 contempor ... Full text Link to item Cite

Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System.

Journal article JACC Cardiovasc Interv · November 9, 2020 OBJECTIVES: The aim of this study was to characterize the safety profile of an intra-annular self-expanding valve with a next-generation low-profile delivery system (DS). BACKGROUND: Key design modifications to the FlexNav DS include the addition of a hydr ... Full text Link to item Cite

Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions 2020 think tank.

Journal article Catheter Cardiovasc Interv · November 2020 The society for cardiovascular angiography and interventions (SCAI) think tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community for high-level ... Full text Link to item Cite

Transcatheter Mitral Valve Replacement With the Transseptal EVOQUE System.

Journal article JACC Cardiovasc Interv · October 26, 2020 OBJECTIVES: The aim of this study was to examine the initial experience with a novel transseptal transcatheter mitral valve replacement (TMVR) system. BACKGROUND: Transseptal TMVR may offer a less invasive option than surgery for mitral regurgitation (MR) ... Full text Link to item Cite

Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial.

Journal article Lancet · September 5, 2020 BACKGROUND: Randomised trial data assessing the safety and efficacy of the self-expanding intra-annular Portico transcatheter aortic valve system (Abbott Structural Heart, St Paul, MN, USA) compared with any commercially available valves are needed to comp ... Full text Link to item Cite

Triage considerations for patients referred for structural heart disease intervention during the COVID-19 pandemic: An ACC/SCAI position statement.

Journal article Catheter Cardiovasc Interv · September 1, 2020 The coronavirus disease-2019 (COVID-19) pandemic has strained health care resources around the world, causing many institutions to curtail or stop elective procedures. This has resulted in an inability to care for patients with valvular and structural hear ... Full text Link to item Cite

Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the COVID-19 Pandemic: An ACC/SCAI Position Statement.

Journal article JACC Cardiovasc Interv · June 22, 2020 The coronavirus disease-2019 (COVID-19) pandemic has strained health care resources around the world, causing many institutions to curtail or stop elective procedures. This has resulted in an inability to care for patients with valvular and structural hear ... Full text Link to item Cite

Percutaneous Atriotomy for Levoatrial-to-Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience.

Journal article JACC Cardiovasc Interv · May 25, 2020 OBJECTIVES: Our study reports the first-in-human experience of a novel approach for left atrial access via the coronary sinus-the percutaneous atriotomy-which is used for left atrial decompression with a dedicated left atrial (LA)-to-coronary sinus (CS) sh ... Full text Link to item Cite

Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies.

Journal article J Am Heart Assoc · April 7, 2020 Background Women have been associated with higher rates of recurrent events after percutaneous coronary intervention than men, possibly attributable to advanced age at presentation and greater comorbidities. These factors also put women at higher risk of b ... Full text Link to item Cite

Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.

Journal article Circulation · March 17, 2020 BACKGROUND: Long-term outcomes in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention with a drug-eluting stent are unclear. Therefore, we aimed to evaluate long-term adverse events in HBR patients undergoing percutaneous cor ... Full text Link to item Cite

Predictors and Risk Calculator of Early Unplanned Hospital Readmission Following Contemporary Self-Expanding Transcatheter Aortic Valve Replacement from the STS/ACC TVT Registry.

Journal article Cardiovasc Revasc Med · March 2020 BACKGROUND: Predictors of hospital readmissions and tools to predict readmissions after TAVR are scarce. Our objective was to identify predictors of early hospital readmission following TAVR in contemporary clinical practice and develop a risk calculator. ... Full text Link to item Cite

The Effect and Relationship of Frailty Indices on Survival After Transcatheter Aortic Valve Replacement.

Journal article JACC Cardiovasc Interv · January 27, 2020 OBJECTIVES: This study sought to evaluate the ability of individual markers of frailty to predict outcomes after transcatheter aortic valve replacement (TAVR) and of their discriminatory value in different age groups. BACKGROUND: Appropriate patient select ... Full text Link to item Cite

Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients.

Journal article Heart · November 2019 OBJECTIVES: This study evaluates the 5-year clinical outcomes of transcatheter mitral valve (MV) repair with the MitraClip device in patients at high risk for MV surgery treated in the Endovascular Valve Edge-to-Edge Repair (EVEREST) II High Risk Study (HR ... Full text Link to item Cite

Comparison of Clinical and Echocardiographic Outcomes After Transcatheter Aortic Valve Implantation With 31-mm CoreValve Versus 34-mm Evolut R Bioprostheses from the STS/ACC TVT Registry.

Journal article Am J Cardiol · October 1, 2019 Transcatheter aortic valve implantation with a bioprosthetic valve of insufficient size is associated with a higher risk of aortic regurgitation (AR). The 31-mm CoreValve and the next generation 34-mm Evolut R bioprostheses were designed to address the nee ... Full text Link to item Cite

Durability and Clinical Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses.

Journal article Circ Cardiovasc Interv · October 2019 BACKGROUND: Valve-in-valve transcatheter aortic valve replacement (TAVR) is an option when a surgical valve demonstrates deterioration and dysfunction. This study reports 3-year results following valve-in-valve with self-expanding TAVR. METHODS: The CoreVa ... Full text Link to item Cite

Self-Expanding Valve System for Treatment of Native Aortic Regurgitation by Transcatheter Aortic Valve Implantation (from the STS/ACC TVT Registry).

Journal article Am J Cardiol · September 1, 2019 Transcatheter aortic valve implantation (TAVI) is approved for treatment of symptomatic aortic stenosis in patients at increased risk for surgical valve replacement, but outcomes data in patients with severe native aortic regurgitation (AR) treated with TA ... Full text Link to item Cite

Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial).

Journal article Am Heart J · May 2019 The Amulet IDE Trial is an ongoing, prospective, randomized, multi-national trial, designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder for stroke prevention in comparison to the WATCHMAN Left Atrial Appe ... Full text Link to item Cite

Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes.

Journal article Am J Cardiol · March 1, 2019 The aim of this study was to examine the patterns and clinical impact of differing modes of dual-antiplatelet therapy (DAPT) cessation after percutaneous coronary intervention (PCI) in patients presenting with and without acute coronary syndromes (ACS). Th ... Full text Link to item Cite

5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients.

Journal article J Am Coll Cardiol · December 4, 2018 BACKGROUND: The CoreValve U.S. Pivotal High Risk Trial was the first randomized trial to show superior 1-year mortality of transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) among high operative mortality-r ... Full text Link to item Cite

Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year: Analysis of the Transcatheter Valve Therapy Registry.

Journal article JAMA Cardiol · December 1, 2018 IMPORTANCE: Improvements in symptoms, functional capacity, and quality of life are among the key goals of edge-to-edge transcatheter mitral valve repair (TMVR) for mitral regurgitation. OBJECTIVE: To examine health status outcomes among patients undergoing ... Full text Link to item Cite

Treatment of Bifurcation Lesions: Has DK Crush"ed" the Competition?

Journal article Curr Cardiol Rep · September 1, 2018 PURPOSE: This paper reviews the double-kiss crush (DK crush) technique in coronary artery bifurcation lesions. The technical aspects of the procedure and the clinical data supporting its use are summarized. RECENT FINDINGS: Randomized studies support the a ... Full text Link to item Cite

Impact of Balloon Predilatation on Hemodynamics and Outcomes After Transcatheter Aortic Valve Implantation With the Self-Expanding CoreValve Prosthesis.

Journal article Am J Cardiol · June 1, 2018 The impact of predilatation (Pre-Dil) on prosthesis hemodynamics and clinical outcomes of subjects who underwent transcatheter aortic valve implantation (TAVI) with a self-expanding prosthesis remains unclear. Two thousand seven hundred twenty-one subjects ... Full text Link to item Cite

Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial.

Journal article Am Heart J · December 2017 BACKGROUND: For patients with severe aortic stenosis (AS) at extreme surgical risk, transcatheter aortic valve replacement (TAVR) leads to improved survival and health status when compared with medical therapy. Whether the early health status benefits of T ... Full text Link to item Cite

Outcomes for the Commercial Use of Self-Expanding Prostheses in Transcatheter Aortic Valve Replacement: A Report From the STS/ACC TVT Registry.

Journal article JACC Cardiovasc Interv · October 23, 2017 OBJECTIVES: The authors sought to compare the outcomes of commercial transcatheter aortic valve replacement (TAVR) with the repositionable Evolut R platform to those observed with the CoreValve device in the Society of Thoracic Surgeons (STS)/American Coll ... Full text Link to item Cite

Causes of death from the randomized CoreValve US Pivotal High-Risk Trial.

Journal article J Thorac Cardiovasc Surg · June 2017 OBJECTIVE: Explore causes and timing of death from the CoreValve US Pivotal High-Risk Trial. METHODS: An independent clinical events committee adjudicated causes of death, followed by post hoc hierarchical classification. Baseline characteristics, early ou ... Full text Link to item Cite

Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?

Journal article Coron Artery Dis · January 2017 Although current everolimus-eluting coronary stents have shown improved event-free survival within the first year following implantation compared with bare-metal stents or earlier generation drug-eluting stents, they remain associated with an ongoing risk ... Full text Link to item Cite

Suction catheter for enhanced control and accuracy of transseptal access.

Journal article EuroIntervention · December 20, 2016 AIMS: Percutaneous structural heart therapies, such as mitral value repair, require site-specific transseptal access (TSA). This can be challenging for interventional cardiologists. We describe a TSA catheter (TSAC) that utilises suction for enhanced contr ... Full text Link to item Cite

Outcomes in the Randomized CoreValve US Pivotal High Risk Trial in Patients With a Society of Thoracic Surgeons Risk Score of 7% or Less.

Journal article JAMA Cardiol · November 1, 2016 IMPORTANCE: Transcatheter aortic valve replacement (TAVR) is now a well-accepted alternative to surgical AVR (SAVR) for patients with symptomatic aortic stenosis at increased operative risk. There is interest in whether TAVR would benefit patients at lower ... Full text Link to item Cite

Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.

Journal article Catheter Cardiovasc Interv · November 2016 The permanent metal prosthesis common to bare metal stents (BMS) as well as both first- and second-generation drug-eluting stents (DES) following treatment of coronary artery disease represents a long-lasting substrate for late adverse coronary events incl ... Full text Link to item Cite

CT and MRI of Aortic Valve Disease: Clinical Update

Journal article Current Radiology Reports · September 1, 2016 Purpose of Review: Imaging of the aortic valve and associated aortic root pathology has historically been primarily imaged by echocardiography. Recent advances in computed tomography (CT) and magnetic resonance (MR) imaging hardware and software have made ... Full text Cite

Safety and Efficacy of Self-Expanding TAVR in Patients With Aortoventricular Angulation.

Journal article JACC Cardiovasc Imaging · August 2016 OBJECTIVES: The aim of this study was to determine the relationship between aortoventricular (AoV) angulation on clinical outcomes after self-expanding transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis who were deemed su ... Full text Link to item Cite

Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials).

Journal article Am J Cardiol · August 1, 2016 Treatment for severe symptomatic aortic stenosis has changed significantly in recent years due to advances in transcatheter aortic valve replacement (TAVR). Recent studies with the CoreValve prosthesis have demonstrated superior results compared with surgi ... Full text Link to item Cite

Predicting Early and Late Mortality After Transcatheter Aortic Valve Replacement.

Journal article J Am Coll Cardiol · July 26, 2016 BACKGROUND: Few studies have examined the impact of novel indices of comorbidity, frailty, and disability on outcomes after transcatheter aortic valve replacement (TAVR). OBJECTIVES: This study analyzed patients from the Medtronic CoreValve U.S. Pivotal Tr ... Full text Link to item Cite

Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study.

Journal article Catheter Cardiovasc Interv · July 2016 BACKGROUND: The Xience V USA Study demonstrated safety and efficacy of the XIENCE V(®) everolimus-eluting stent (EES) in a large, prospective study of a real-world, unselected patient population. There is limited long-term data regarding EES performance in ... Full text Link to item Cite

3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement.

Journal article J Am Coll Cardiol · June 7, 2016 BACKGROUND: In patients with severe aortic stenosis at increased risk for surgery, self-expanding transcatheter aortic valve replacement (TAVR) is associated with improved 2-year survival compared with surgery. OBJECTIVES: This study sought to determine wh ... Full text Link to item Cite

Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.

Journal article JACC Cardiovasc Interv · January 25, 2016 OBJECTIVES: The purpose of this study was to characterize outcomes for everolimus-eluting stent (EES)-treated subjects according to treatment with continued thienopyridine plus aspirin versus aspirin alone 12 to 30 months after stenting. BACKGROUND: In the ... Full text Link to item Cite

Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II.

Journal article J Am Coll Cardiol · December 29, 2015 BACKGROUND: In EVEREST II (Endovascular Valve Edge-to-Edge Repair Study), treatment of mitral regurgitation (MR) with a novel percutaneous device showed superior safety compared with surgery, but less effective reduction in MR at 1 year. OBJECTIVES: This s ... Full text Link to item Cite

The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug-eluting stent: Current concepts and overview of clinical evidence.

Journal article Catheter Cardiovasc Interv · October 2015 The advent of fully bioresorbable stent technology and specifically the ABSORB™, a bioresorbable vascular scaffold (BVS) stent, is heralded as breakthrough technology in the current era of percutaneous coronary interventions. This article reviews the curre ... Full text Link to item Cite

2-Year Outcomes After Iliofemoral Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery.

Journal article J Am Coll Cardiol · September 22, 2015 BACKGROUND: We reported favorable 1-year outcomes in patients unsuitable for surgery who underwent self-expanding transcatheter aortic valve replacement (TAVR) compared with an objective performance goal. Longer-term outcomes in these patients are not know ... Full text Link to item Cite

2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement.

Journal article J Am Coll Cardiol · July 14, 2015 BACKGROUND: The U.S. pivotal trial for the self-expanding valve found that among patients with severe aortic stenosis at increased risk for surgery, the 1-year survival rate was 4.9 percentage points higher in patients treated with a self-expanding transca ... Full text Link to item Cite

Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.

Journal article Circ Cardiovasc Interv · May 2015 BACKGROUND: Whether premature dual antiplatelet therapy (DAPT) interruption is safe in patients receiving cobalt chromium everolimus-eluting stents remains controversial. We sought to examine the relationship between DAPT discontinuation and stent thrombos ... Full text Link to item Cite

A prospective, randomized, pivotal trial of a novel extravascular collagen-based closure device compared to manual compression in diagnostic and interventional patients.

Journal article J Invasive Cardiol · March 2015 OBJECTIVES: The RESPECT trial was aimed at evaluating safety/efficacy of a new extravascular closure system in diagnostic (Dx) and interventional (Ix) procedures performed through 6 or 7 Fr introducer sheaths. BACKGROUND: Although vascular closure devices ... Link to item Cite

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Journal article N Engl J Med · December 4, 2014 BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent ... Full text Link to item Cite

Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery.

Journal article J Thorac Cardiovasc Surg · December 2014 OBJECTIVES: The CoreValve Extreme Risk US Pivotal Trial enrolled patients with symptomatic severe aortic stenosis deemed unsuitable for surgical aortic valve replacement. Implants were attempted using transfemoral access (n = 489) or an alternative access ... Full text Link to item Cite

Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents.

Journal article J Invasive Cardiol · September 2014 BACKGROUND: Although percutaneous coronary intervention with everolimus-eluting stent (EES) implantation for native coronary artery disease has favorable results compared to first-generation drug-eluting stents, outcomes with EES for the treatment of in-st ... Link to item Cite

Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: one year results from the XIENCE V® USA condition of approval post-market study.

Journal article Catheter Cardiovasc Interv · July 1, 2014 OBJECTIVES: The purpose of this study was to evaluate the 1-year clinical outcomes of more complex XIENCE V USA real-world patients with small versus nonsmall vessel lesions. BACKGROUND: Patients with small vessel lesions undergoing coronary stent placemen ... Full text Link to item Cite

Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery.

Journal article J Am Coll Cardiol · May 20, 2014 OBJECTIVES: This study sought to evaluate the safety and efficacy of the CoreValve transcatheter heart valve (THV) for the treatment of severe aortic stenosis in patients at extreme risk for surgery. BACKGROUND: Untreated severe aortic stenosis is a progre ... Full text Link to item Cite

Transcatheter aortic-valve replacement with a self-expanding prosthesis.

Journal article N Engl J Med · May 8, 2014 BACKGROUND: We compared transcatheter aortic-valve replacement (TAVR), using a self-expanding transcatheter aortic-valve bioprosthesis, with surgical aortic-valve replacement in patients with severe aortic stenosis and an increased risk of death during sur ... Full text Link to item Cite

5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Journal article JACC Cardiovasc Interv · December 2013 OBJECTIVES: This study sought to evaluate the long-term safety and efficacy of everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES) in patients with obstructive coronary artery disease. BACKGROUND: The use of EES compared to PES has been sho ... Full text Link to item Cite

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.

Journal article Lancet · November 23, 2013 BACKGROUND: Dual antiplatelet therapy (DAPT) cessation increases the risk of adverse events after percutaneous coronary intervention (PCI). Whether risk changes over time, depends on the underlying reason for DAPT cessation, or both is unknown. We assessed ... Full text Link to item Cite

Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.

Journal article Catheter Cardiovasc Interv · October 1, 2013 OBJECTIVES: The objective of this analysis was to evaluate the safety and effectiveness of XIENCE V in acute myocardial infarction (AMI). BACKGROUND: The XIENCE V(®) Everolimus-eluting coronary stent was superior to the TAXUS(®) paclitaxel-eluting stent in ... Full text Link to item Cite

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Journal article JACC Cardiovasc Interv · September 2013 OBJECTIVES: This study sought to investigate whether the everolimus-eluting stent (EES) is superior to the paclitaxel-eluting stent (PES) with respect to long-term individual clinical outcomes. BACKGROUND: Individual studies have indicated a clinical advan ... Full text Link to item Cite

4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation.

Journal article J Am Coll Cardiol · July 23, 2013 OBJECTIVES: This study sought to evaluate 4-year outcomes of percutaneous repair versus surgery for mitral regurgitation. BACKGROUND: Transcatheter therapies are being developed to treat valvular heart disease. In the EVEREST (Endovascular Valve Edge-to-Ed ... Full text Link to item Cite

Percutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling.

Journal article Circ Cardiovasc Imaging · July 2013 BACKGROUND: Percutaneous repair of mitral regurgitation (MR) permits examination of the effect of MR reduction without surgery and cardiopulmonary bypass on left ventricular (LV) dimensions and function. The goal of this analysis was to determine the exten ... Full text Link to item Cite

Percutaneous saphenous vein graft and arterial graft intervention

Book section · January 1, 2013 Despite major advances in the management of these lesions over the past decade, bypass-graft intervention remains a significant challenge. Saphenous vein graft (SVG) intervention in particular has a high complication rate, a consequence of frequent distal ... Full text Cite

Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study.

Journal article J Interv Cardiol · December 2012 OBJECTIVES: This 2-year follow-up of the XIENCE V USA study examines both the long-term safety and effectiveness of the everolimus-eluting coronary stent system (EECSS) in real-world patients. BACKGROUND: The safety and effectiveness of EECSS at 1 year in ... Full text Link to item Cite

Outcomes for functional mitral regurgitation

Book section · August 17, 2012 Cite

Xience side branch access stent for treatment of bifurcation coronary disease: a review of preclinical data.

Journal article J Interv Cardiol · August 2012 The Xience Side Branch Access (SBA) stent is an everolimus-eluting stent designed specifically for branching coronary geometry, providing wire access into the side branch (SB) regardless of the planned treatment strategy. The stent is delivered via a low-p ... Full text Link to item Cite

StarClose vascular closure system (VCS) is safe and effective in patients who ambulate early following successful femoral artery access closure--results from the RISE clinical trial.

Journal article Catheter Cardiovasc Interv · July 1, 2012 OBJECTIVE: The RISE study was a prospective, multicenter, single-arm study evaluating the safety and efficacy of the StarClose Vascular Closure System (VCS) in the femoral artery in subjects who were ambulated early following percutaneous diagnostic corona ... Full text Link to item Cite

Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years.

Journal article Am J Cardiol · July 1, 2012 Routine angiographic follow-up after bare-metal stent implantation has been associated with an increase in coronary revascularization. The impact of angiographic follow-up after drug-eluting stent placement remains poorly characterized. The prospective, ra ... Full text Link to item Cite

Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.

Journal article JACC Cardiovasc Interv · June 2012 OBJECTIVES: The aim of this study was to identify predictors of clinical events after XIENCE V (Abbott Vascular, Santa Clara, California) stenting. BACKGROUND: The XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System [EECSS] USA Post-Approval) s ... Full text Link to item Cite

A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trial.

Journal article Int J Cardiol · May 17, 2012 BACKGROUND/OBJECTIVES: The purpose of this prospective, randomized, single-blind controlled clinical trial was to compare the effectiveness of a zotarolimus-eluting stent (ZoMaxx™) with a paclitaxel-eluting coronary stent (Taxus™ Express(2)™) in patients w ... Full text Link to item Cite

Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials.

Journal article EuroIntervention · May 15, 2012 AIMS: The impact of age on outcomes following everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) implantation was evaluated in a patient-level pooled analysis of the SPIRIT III (n=1,002) and SPIRIT IV (n=3,687) trials. METHODS AND RESULTS: Cl ... Full text Link to item Cite

Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial.

Journal article J Am Coll Cardiol · April 3, 2012 OBJECTIVES: The purpose of this study was to characterize patients with mitral regurgitation (MR) and atrial fibrillation (AF) treated percutaneously using the MitraClip device (Abbott Vascular, Abbott Park, Illinois) and compare the results with surgery i ... Full text Link to item Cite

Evaluation and treatment of coronary bifurcation disease: Current strategies and new technologies

Journal article Interventional Cardiology · April 1, 2012 Coronary bifurcation lesions make up 15-20% of all percutaneous coronary interventions and remain a therapeutic challenge. Drug-eluting stents are the preferred stent choice for these interventions. Four large randomized trials (NORDIC, CACTUS, BBC One and ... Full text Cite

Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions.

Journal article Circ Cardiovasc Interv · April 2012 BACKGROUND: A consensus definition for periprocedural myocardial infarction (MI) in coronary stent trials has not been established. Differences between a historic definition, based on modified World Health Organization (WHO) criteria, and a proposed univer ... Full text Link to item Cite

Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents.

Journal article EuroIntervention · January 2012 AIMS: To evaluate whether the improved outcomes with newer generation drug-eluting stents (DES) utilising thin-strut stents are consistent among different patient and angiographic subgroups. METHODS AND RESULTS: Clinical outcomes over three years were coll ... Full text Link to item Cite

A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).

Journal article JACC Cardiovasc Interv · December 2011 OBJECTIVES: The XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System Condition-of-Approval Post-Market study) sought to: 1) evaluate the safety of everolimus-eluting coronary stent systems (EECSS) in a contemporary cohort of real-world subjects; ... Full text Link to item Cite

Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials.

Journal article J Interv Cardiol · December 2011 BACKGROUND: Higher rates of adverse cardiac events have been observed in patients with small vessel disease. Therefore, we compared an everolimus-eluting stent (EES) to a paclitaxel-eluting stent (PES) for treatment of small (reference vessel diameter: RVD ... Full text Link to item Cite

Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials.

Journal article J Interv Cardiol · August 2011 The XIENCE V® Everolimus-Eluting Coronary Stent System (EECSS) has been evaluated in multiple randomized controlled trials (RCTs) with several different comparators (SPIRIT FIRST, SPIRIT II, SPIRIT III, SPIRIT IV, COMPARE, ISAR-TEST 4, SORT-OUT IV, and RES ... Full text Link to item Cite

A nonimaging catheter for measurement of coronary artery lumen area: a first in man pilot study.

Journal article Catheter Cardiovasc Interv · August 1, 2011 OBJECTIVES: The objective of this human pilot study was to determine the safety and the level of agreement between a novel nonimaging 2.7 Fr. catheter-based system (LumenRECON, LR) that uses electrical conductance for measurement of lumen cross-sectional a ... Full text Link to item Cite

Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.

Journal article EuroIntervention · July 2011 AIMS: Age is an important determinant of outcomes in patients treated with percutaneous coronary intervention (PCI). This report from the randomised multicentre SPIRIT III trial compares the outcomes in elderly and younger patients treated with everolimus- ... Full text Link to item Cite

Presentation and therapy of spontaneous coronary artery dissection and comparisons of postpartum versus nonpostpartum cases.

Journal article Am J Cardiol · June 1, 2011 Predisposing risk factors, clinical course, and prognosis of spontaneous coronary artery dissection (SCAD) remain poorly understood. We reviewed medical records and coronary angiograms of patients admitted to our institution with the diagnosis of SCAD from ... Full text Link to item Cite

The acute hemodynamic effects of MitraClip therapy.

Journal article J Am Coll Cardiol · April 19, 2011 OBJECTIVES: The objective of this study was to evaluate the acute hemodynamic consequences of mitral valve (MV) repair with the MitraClip device (Abbott Vascular, Menlo Park, California). BACKGROUND: Whether surgical correction of mitral regurgitation (MR) ... Full text Link to item Cite

Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial).

Journal article Am J Cardiol · March 15, 2011 Women treated with the XIENCE V have improved 1-year clinical outcomes compared to women treated with TAXUS; whether benefits in women are sustained at 3 years is unknown. Three-year follow-up of the SPIRIT III trial revealed improved clinical outcomes of ... Full text Link to item Cite

Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial).

Journal article Am J Cardiol · March 15, 2011 The safety and efficacy of the XIENCE V everolimus-eluting stent (EES) compared to the Taxus Express(2) paclitaxel-eluting stent (PES) has been demonstrated through 2 years in the SPIRIT II and III randomized clinical trials, but limited longer-term data h ... Full text Link to item Cite

An integer based risk score for predicting 30-day major adverse cardiac or cerebrovascular events after percutaneous coronary intervention with drug-eluting stents: results from a large prospective multicentre registry, the STENT Group.

Journal article EuroIntervention · March 2011 AIMS: Previous risk models predicting in-hospital major adverse cardiac or cerebrovascular events (MACCE) after percutaneous coronary interventions (PCI) may underestimate actual short-term post-procedure complications due to the trend toward early dischar ... Full text Link to item Cite

Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.

Journal article EuroIntervention · December 2010 AIMS AND METHODS: The rates of side branch occlusion and subsequent periprocedural MI during everolimus-eluting stent (EES) and paclitaxel-eluting stent (PES) placement were examined in the randomised SPIRIT III trial. Periprocedural myocardial infarction ... Full text Link to item Cite

Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.

Journal article JACC Cardiovasc Interv · December 2010 OBJECTIVES: The purpose of this study was to investigate long-term 3-year clinical outcomes of an everolimus-eluting stent (EES) versus a paclitaxel-eluting stent (PES). BACKGROUND: Compared with PES, EES reduced target vessel failure and major adverse car ... Full text Link to item Cite

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.

Journal article JACC Cardiovasc Interv · December 2010 OBJECTIVES: We evaluated outcomes following XIENCE V everolimus-eluting stent (EES) compared with the Taxus Express(2) paclitaxel-eluting stent (PES) in patients undergoing multilesion and multivessel intervention. BACKGROUND: The optimal revascularization ... Full text Link to item Cite

Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial.

Journal article Catheter Cardiovasc Interv · November 1, 2010 OBJECTIVE: To evaluate whether an everolimus-eluting stent (EES) with thinner stent struts and polymer results in less periprocedural myonecrosis and adverse outcomes. BACKGROUND: Higher periprocedural myocardial infarction (MI) rates have been reported wi ... Full text Link to item Cite

Percutaneous coronary intervention for small-vessel coronary disease: highlight on the everolimus-eluting stent.

Journal article Expert Rev Cardiovasc Ther · September 2010 Smaller coronary arteries are less able to accommodate late loss after percutaneous coronary interventions than larger arteries. The first-generation drug-eluting stents have been shown to have better control of neo-intimal hyperplasia and lower late lumen ... Full text Link to item Cite

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.

Journal article EuroIntervention · September 2010 AIMS: To examine the two year clinical outcomes in dual-vessel disease from the SPIRIT III trial comparing the XIENCE V(r) everolimus-eluting stent (EES) to the TAXUS Express2(tm) paclitaxel-eluting stent (PES). METHODS AND RESULTS: From a total of 1,002 r ... Full text Link to item Cite

The unrelenting challenge of vein graft disease.

Journal article J Invasive Cardiol · June 2010 Link to item Cite

A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.

Journal article EuroIntervention · February 2010 AIMS: To assess the safety and efficacy of the XIENCE V everolimus-eluting stent (EES) compared to the TAXUS paclitaxel-eluting stent (PES) in women at two years. METHODS AND RESULTS: In this pooled analysis, a cohort of 395 women and 906 men was studied b ... Full text Link to item Cite

Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry.

Journal article Catheter Cardiovasc Interv · February 1, 2010 OBJECTIVE: This study evaluates the safety and efficacy of the XIENCE V 4.0 mm stent for the treatment of de novo native coronary artery lesions. BACKGROUND: In the SPIRIT III trial, the XIENCE V everolimus-eluting stent (EES), compared with the TAXUS EXPR ... Full text Link to item Cite

Contemporary bifurcation treatment strategies: the role of currently available slotted tube stents.

Journal article Rev Cardiovasc Med · 2010 Treatment of coronary bifurcation lesions remains complicated and fraught with procedural challenges. Although numerous techniques have been proposed for treating bifurcations, no approach completely circumvents the limitations of the current stent platfor ... Full text Link to item Cite

A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Journal article J Am Coll Cardiol · December 8, 2009 OBJECTIVES: Our aim was to investigate the safety and efficacy of intravenous allogeneic human mesenchymal stem cells (hMSCs) in patients with myocardial infarction (MI). BACKGROUND: Bone marrow-derived hMSCs may ameliorate consequences of MI, and have the ... Full text Link to item Cite

Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).

Journal article JACC Cardiovasc Interv · December 2009 OBJECTIVES: The pivotal TAXUS IV (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent) trial evaluated the long-term safety and effectiveness of the paclitaxel-eluting stent (PES) compared with an otherwise identical ... Full text Link to item Cite

Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial.

Journal article Am Heart J · December 2009 BACKGROUND: Drug-eluting stents with low late loss may be particularly beneficial in small coronary arteries. We therefore examined whether the everolimus-eluting stent is superior to the paclitaxel-eluting stent in patients treated with 2.5-mm stents in t ... Full text Link to item Cite

Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.

Journal article JACC Cardiovasc Interv · November 2009 OBJECTIVES: This study compares outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients undergoing saphenous vein graft (SVG) intervention. BACKGROUND: The safety and efficacy of DES in patients undergoing SVG intervention is contr ... Full text Link to item Cite

Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort.

Journal article J Am Coll Cardiol · August 18, 2009 OBJECTIVES: We undertook a prospective multicenter single-arm study to evaluate the feasibility, safety, and efficacy of the MitraClip system (Evalve Inc., Menlo Park, California). BACKGROUND: Mitral valve repair for mitral regurgitation (MR) has been perf ... Full text Link to item Cite

A randomized comparison of a novel bioabsorbable vascular closure device versus manual compression in the achievement of hemostasis after percutaneous femoral procedures: the ECLIPSE (Ensure's Vascular Closure Device Speeds Hemostasis Trial).

Journal article JACC Cardiovasc Interv · August 2009 OBJECTIVES: This trial compared the performance of a novel bioabsorbable vascular closure device (VCD) versus manual compression (MC) for access site hemostasis in patients undergoing percutaneous trans-femoral coronary or peripheral procedures. BACKGROUND ... Full text Link to item Cite

A novel system for the reconstruction of a coronary artery lumen profile in real time: a preclinical validation.

Journal article Am J Physiol Heart Circ Physiol · July 2009 Accurate sizing of vessel diameter is important for understanding the physiology of blood vessels as well as the treatment of coronary and peripheral artery disease. The objective of this study was to validate a novel catheter-based system [the LumenRECON ... Full text Link to item Cite

Effects of stent sizing on endothelial and vessel wall stress: potential mechanisms for in-stent restenosis.

Journal article J Appl Physiol (1985) · May 2009 Stent sizing and apposition have been shown to be important determinants of clinical outcome. This study evaluates the mechanical effects of undersizing and oversizing of stents on endothelial wall shear stress (WSS) and vessel wall stress to determine a p ... Full text Link to item Cite

A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial).

Journal article Circ Cardiovasc Interv · April 2009 BACKGROUND: AVID (Angiography Versus Intravascular ultrasound-Directed stent placement) is a multicenter, randomized controlled trial designed to assess the effect of intravascular ultrasound (IVUS)-directed stent placement on the 12-month rate of target l ... Full text Link to item Cite

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Journal article Circulation · February 10, 2009 BACKGROUND: In the prospective randomized Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial, an everolimus-eluting stent (EES) compared w ... Full text Link to item Cite

Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group.

Journal article Catheter Cardiovasc Interv · December 1, 2008 OBJECTIVES: This study compares outcomes with drug-eluting stents (DES) versus bare metal stents (BMS) in patients with ST-elevation myocardial infarction (STEMI). BACKGROUND: DESs have been effective in elective percutaneous coronary intervention (PCI), b ... Full text Link to item Cite

Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.

Journal article JACC Cardiovasc Interv · August 2008 OBJECTIVES: This study evaluates outcomes and complications in patients treated with drug-eluting stents (DES) for "off-label" indications. BACKGROUND: Drug-eluting stents have been effective in randomized trials, but their safety and efficacy for off-labe ... Full text Link to item Cite

Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.

Journal article JAMA · April 23, 2008 CONTEXT: A thin, cobalt-chromium stent eluting the antiproliferative agent everolimus from a nonadhesive, durable fluoropolymer has shown promise in preliminary studies in improving clinical and angiographic outcomes in patients with coronary artery diseas ... Full text Link to item Cite

A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.

Journal article J Am Coll Cardiol · April 22, 2008 OBJECTIVES: The aim was to compare safety and effectiveness of the CoStar drug-eluting stent (DES) (Conor MedSystems, Menlo Park, California) with those of the Taxus DES (Boston Scientific, Maple Grove, Minnesota) in de novo single- and multivessel percuta ... Full text Link to item Cite

Efficacy of a novel procedure sheath and closure device during diagnostic catheterization: the multicenter randomized clinical trial of the FISH device.

Journal article J Invasive Cardiol · April 2008 BACKGROUND: The aim of vascular closure devices is to safely secure the arterial access site at the conclusion of catheterization procedures, thereby increasing patient comfort and decreasing time to hemostasis and ambulation. The FISH (femoral introducer ... Link to item Cite

Bifurcation coronary artery disease: current techniques and future directions (part 1).

Journal article J Invasive Cardiol · February 2008 The treatment of bifurcation coronary artery disease is a common challenge facing the interventional cardiologist. There have been major advances in techniques as well as more widespread use of drug-eluting stents; both appear to have contributed to the re ... Link to item Cite

Embolic protection: the FilterWire EZ Embolic Protection System.

Journal article Expert Rev Med Devices · January 2008 The field of interventional cardiology has grown dramatically over the past 30 years, including recent advances in the area of peripheral vascular intervention. The phenomenon of no-reflow, characterized by a reduction in coronary blood flow during vascula ... Full text Link to item Cite

The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial.

Journal article J Am Coll Cardiol · October 9, 2007 OBJECTIVES: To determine if outcomes could be further improved, we investigated an embolic protection device placed proximal to the target lesion that could provide protection before lesion instrumentation, allow the use of conventional guidewires, and per ... Full text Link to item Cite

Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.

Journal article J Am Coll Cardiol · September 25, 2007 OBJECTIVES: The purpose of this study was to compare the 9-month clinical outcomes of patients treated with paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES) for coronary artery stenosis. BACKGROUND: The STENT (Strategic Transcatheter Evalu ... Full text Link to item Cite

Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.

Journal article Am Heart J · May 2007 BACKGROUND: This study compared VLTS-589 (plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188) with poloxamer 188 control, for the treatment of intermittent claudication in patients with moderate to severe peripheral arterial d ... Full text Link to item Cite

The safety and efficacy of the StarClose Vascular Closure System: the ultrasound substudy of the CLIP study.

Journal article Catheter Cardiovasc Interv · November 2006 BACKGROUND: The StarClose Vascular Closure System (Abbott Vascular, Redwood City, CA) features a nitinol clip that is designed to achieve closure of the femoral arteriotomy access site. The CLIP Study was performed to assess the safety and efficacy of Star ... Full text Link to item Cite

The StarClose Vascular Closure System: interventional results from the CLIP study.

Journal article Catheter Cardiovasc Interv · November 2006 BACKGROUND: The StarClose Vascular Closure System is a femoral access site closure technology that uses a flexible nitinol clip to complete a circumferential, extravascular arteriotomy close. The Clip CLosure In Percutaneous Procedures study was initiated ... Full text Link to item Cite

Bypass graft disease: Role of embolic protection and drug-eluting stents

Journal article Journal of Interventional Cardiology · October 1, 2006 Vein graft intervention is particularly challenging, both because of the high risk of procedural complications due to embolization and the high rate of subsequent target vessel failure. Clearly the use of embolic protection is mandatory except in the case ... Full text Cite

Commentary: Bifurcations: the problem is the side branch.

Journal article J Invasive Cardiol · October 2006 Link to item Cite

Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.

Journal article J Am Coll Cardiol · July 18, 2006 OBJECTIVES: This study sought to compare aggregate medical care costs for patients undergoing percutaneous coronary intervention with paclitaxel-eluting stents (PES) and bare-metal stents (BMS) and to formally evaluate the incremental cost effectiveness of ... Full text Link to item Cite

Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.

Journal article J Am Coll Cardiol · July 4, 2006 OBJECTIVES: The objectives of the study were to evaluate the effect of angiographic follow-up on revascularization rates in the TAXUS-IV trial and to determine whether the relative benefit of paclitaxel-eluting stent implantation compared with bare metal s ... Full text Link to item Cite

Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.

Journal article Eur Heart J · April 2006 AIMS: Although embolic protection devices reduce complications during saphenous vein graft (SVG) stenting, adverse events still occur in approximately 10% of patients. IIb/IIIa antagonists have not been proven effective during SVG intervention. We hypothes ... Full text Link to item Cite

Bifurcation intervention: keep it simple.

Journal article J Invasive Cardiol · February 2006 Link to item Cite

Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: Results from the FIRE trial

Journal article American Heart Journal · January 1, 2006 Background: The filter-based FilterWire EX (Boston Scientific, Natick, MA) embolic protection system and the GuardWire (Medtronic, Santa Rosa, CA) balloon occlusion and aspiration device have been previously shown to reduce periprocedural complication rate ... Full text Cite

Clinical experience with a circumferential clip-based vascular closure device in diagnostic catheterization.

Journal article J Invasive Cardiol · October 2005 BACKGROUND: The StarClose Vascular Closure System (Abbott Vascular Devices, Redwood City, California) utilizes a small, flexible nitinol clip to complete a circumferential, extravascular closure of the femoral arteriotomy site. The StarClose is an investig ... Link to item Cite

Contemporary management of vein graft disease.

Journal article J Invasive Cardiol · August 2005 Link to item Cite

Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial.

Journal article J Am Coll Cardiol · April 19, 2005 OBJECTIVES: We sought to evaluate the relationship between angiographic late loss and clinical outcomes in the drug-eluting stent era. BACKGROUND: The interrelationship between angiographic late loss, binary restenosis, and clinical recurrence (target lesi ... Full text Link to item Cite

Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial.

Journal article J Am Coll Cardiol · April 19, 2005 OBJECTIVES: The aim of this study was to use serial volumetric intravascular ultrasound (IVUS) to evaluate the effects of polymer-based, paclitaxel-eluting stents on in-stent neointima formation and late incomplete stent apposition. BACKGROUND: The TAXUS-I ... Full text Link to item Cite

Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.

Journal article J Am Coll Cardiol · April 19, 2005 OBJECTIVES: We sought to determine the safety and efficacy of polymer-regulated site-specific delivery of paclitaxel in patients with diabetes mellitus undergoing stent implantation. BACKGROUND: Percutaneous coronary intervention in patients with diabetes ... Full text Link to item Cite

Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention.

Journal article Am J Cardiol · March 1, 2005 We sought to determine the influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention. From the Filterwire EX Randomized Evaluation trial, in which patients who underwent saphenous vein graft stenting ... Full text Link to item Cite

Drug-eluting stents in the management of coronary artery disease: Implications for payors and hospitals

Journal article Disease Management and Health Outcomes · February 15, 2005 Of the >1 million patients who undergo coronary intervention in the US annually, 10-45% develop stent restenosis. Designed to inhibit tissue growth following coronary intervention, the drug-eluting stent (DES) is a breakthrough technology that has been sho ... Full text Cite

Approach to the patient with prior bypass surgery.

Journal article J Interv Cardiol · October 2004 Full text Link to item Cite

Contemporary treatment of small-vessel disease.

Journal article J Invasive Cardiol · August 2004 Link to item Cite

One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.

Journal article Circulation · April 27, 2004 BACKGROUND: The safety and efficacy of the slow-release, polymer-based, paclitaxel-eluting stent after implantation in a broad cross section of de novo coronary lesions at 1 year are unknown. METHODS AND RESULTS: In the TAXUS-IV trial, 1314 patients with s ... Full text Link to item Cite

Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study).

Journal article Am J Cardiol · March 1, 2004 In a nonrandomized feasibility study of therapeutic hypothermia in acute myocardial infarction, 18 patients were treated with endovascular cooling (Alsius, Irvine, California) as adjunctive therapy to primary percutaneous coronary intervention to assess me ... Full text Link to item Cite

Role of enoxaparin in the invasive management of the ACS patient.

Journal article J Invasive Cardiol · February 2004 Link to item Cite

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Journal article N Engl J Med · January 15, 2004 BACKGROUND: Restenosis after coronary stenting necessitates repeated percutaneous or surgical revascularization procedures. The delivery of paclitaxel to the site of vascular injury may reduce the incidence of neointimal hyperplasia and restenosis. METHODS ... Full text Link to item Cite

Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries.

Journal article J Am Coll Cardiol · December 3, 2003 OBJECTIVES: We sought to determine whether routine thrombectomy prior to stent implantation in diseased saphenous vein grafts (SVGs) and thrombus-containing native coronary arteries would reduce peri-procedural myonecrosis and subsequently enhance event-fr ... Full text Link to item Cite

A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study.

Journal article J Am Coll Cardiol · September 17, 2003 OBJECTIVES: The aim of this study was to discern a target range of anticoagulation for enoxaparin during percutaneous coronary intervention (PCI) as measured by the Rapidpoint ENOX (Pharmanetics Inc., Morrisville, North Carolina), a new point-of-care test. ... Full text Link to item Cite

Usefulness of a cobalt chromium coronary stent alloy.

Journal article Am J Cardiol · August 15, 2003 The cobalt chromium Guidant Multi-Link Vision coronary stent was deployed in 267 patients as part of a multicenter international registry. Major adverse cardiovascular events were infrequent, and late (180 days) quantitative angiography demonstrated binary ... Full text Link to item Cite

Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts.

Journal article Circulation · August 5, 2003 BACKGROUND: The high rate of periprocedural complications resulting from atherothrombotic embolization after percutaneous intervention in diseased saphenous vein grafts is reduced by distal microcirculatory protection using a balloon occlusion and aspirati ... Full text Link to item Cite

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.

Journal article Lancet · June 15, 2002 BACKGROUND: Recombinant fibroblast growth factor-2 (rFGF-2) improves perfusion in models of myocardial and hindlimb ischaemia. We investigated whether one or two doses of intra-arterial rFGF-2 improves exercise capacity in patients with moderate-to-severe ... Full text Link to item Cite

Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial.

Journal article Am Heart J · January 2002 BACKGROUND: Adjunctive therapies that increase the incidence of normal reperfusion after thrombolysis for acute myocardial infarction (MI) could enhance clinical outcomes. Direct thrombin inhibitors may offer an advantage over standard adjunctive therapies ... Full text Link to item Cite

Balloon angioplasty.

Journal article J Interv Cardiol · October 2001 Full text Link to item Cite

Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial.

Journal article Am J Cardiol · July 15, 2001 The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) is a large, randomized, placebo-controlled, regimen-finding trial of intra-arterial recombinant fibroblast growth factor-2 in patients with int ... Full text Link to item Cite

Guides and wires.

Journal article J Interv Cardiol · February 2001 Full text Link to item Cite

Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries.

Journal article Am J Cardiol · January 15, 2001 The NIR stent is a novel second generation tubular stent that was designed to overcome some of the limitations of the earlier Palmaz-Schatz (PS) stent design. The NIR Vascular Advanced North American (NIRVANA) trial randomized 849 patients with single coro ... Full text Link to item Cite

Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials).

Journal article Am J Cardiol · August 1, 2000 The cumulative experience of 4 clinical trials using the MULTI-LINK coronary stent design was analyzed. Multivariable logistic regression identified postprocedure in-stent minimum lumen diameter (p = 0.0001), stent length (p = 0.0038), smoking (p = 0.0105) ... Full text Link to item Cite

Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial.

Journal article Circulation · May 9, 2000 BACKGROUND: Previous in vitro and in vivo studies have suggested an association between thrombus-related events and type of contrast media. Low osmolar contrast agents appear to improve the safety of diagnostic and coronary artery interventional procedures ... Full text Link to item Cite

Efficacy of abciximab readministration in coronary intervention.

Journal article Am J Cardiol · February 15, 2000 Abciximab, an Fab monoclonal antibody fragment that blocks the platelet glycoprotein IIb/IIIa receptor, is increasingly used as an adjunct to coronary intervention. Little is known, however, about the efficacy and safety of readministration of abciximab. T ... Full text Link to item Cite

Procedural and late outcomes following MULTI-LINK DUET coronary stent deployment.

Journal article Am J Cardiol · December 15, 1999 The MULTI-LINK DUET is the next generation MULTI-LINK stent with modified strut geometry. Safety and efficacy of the MULTI-LINK DUET were evaluated in a prospective multicenter registry and were compared with prior MULTI-LINK stent experience from the ASCE ... Full text Link to item Cite

Economic considerations in the use of the platelet GP IIb/IIIa inhibitor abciximab in percutaneous coronary intervention

Conference European Heart Journal Supplement · July 10, 1999 Multiple, large-scale randomized clinical trials have shown that platelet glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor treatment in patients undergoing percutaneous coronary intervention is safe and effective in reducing the occurrence of adverse ischaemi ... Cite

Comparison of immediate and in-hospital results of conventional balloon and perfusion balloon angioplasty using intracoronary ultrasound.

Journal article Am J Cardiol · February 1, 1999 Angiographic studies have demonstrated that perfusion balloon percutaneous transluminal coronary angioplasty (PTCA) may result in modestly improved luminal gains and fewer major dissections than conventional balloon PTCA. However, intracoronary ultrasound ... Full text Link to item Cite

New intracoronary stent designs: form follows function versus function follows form.

Journal article Curr Opin Cardiol · July 1998 Intracoronary stenting improves the acute and long-term safety and efficacy of percutaneous coronary interventions by minimizing the risks of abrupt closure and late restenosis. Enhanced designs of new coronary stents will continue to expand the spectrum o ... Full text Link to item Cite

Quantitative coronary angiographic and intravascular ultrasound assessment of a new nonarticulated stent: report from the Advanced Cardiovascular Systems MultiLink stent pilot study.

Journal article J Am Coll Cardiol · January 1998 OBJECTIVES: The purpose of this study was to evaluate the safety, feasibility, optimal deployment technique and 1-year clinical outcome for the Advanced Cardiovascular Systems (ACS) MultiLink stent. BACKGROUND: Optimal stent deployment assessed by quantita ... Full text Link to item Cite

Update on management of in-stent restenosis

Conference Journal of Interventional Cardiology · January 1, 1998 In-stent restenosis (ISR) is a common and frequently resistant problem. The pathophysiology of in-stent and nonstent restenosis is different, the former resulting primarily from intimal hyperplasia, while the latter is predominantly a consequence of negati ... Full text Cite

Influence of coronary atherosclerotic remodeling on the mechanism of balloon angioplasty.

Journal article Am Heart J · December 1997 OBJECTIVES: Intracoronary ultrasonography was used to assess coronary arteries before and after balloon percutaneous transluminal coronary angioplasty (PTCA) to determine whether the mode of coronary atherosclerotic remodeling affects the mechanism of ball ... Full text Link to item Cite

Comparison of six-month outcome of coronary artery stenting in patients <65, 65-75, and >75 years of age.

Journal article Am J Cardiol · October 15, 1997 We studied 1,238 patients receiving 1,880 coronary stents. In-hospital outcomes were divided by age into <65 years (n = 747, group 1), 65 to 75 years (n = 326, group 2), and >75 years (n = 165, group 3). Procedural success was 97.2%, 95.1%, and 98.8% in gr ... Full text Link to item Cite

QRS changes during percutaneous transluminal coronary angioplasty and their possible mechanisms.

Journal article J Am Coll Cardiol · August 1997 OBJECTIVES: The purpose of the study was to describe the configuration, and investigate the mechanisms, of QRS changes occurring during percutaneous transluminal coronary angioplasty (PTCA). BACKGROUND: QRS changes during PTCA have been attributed to both ... Full text Link to item Cite

Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures--Part VI.

Journal article Clin Cardiol · February 1997 Catheter balloon angioplasty is a well accepted form of nonsurgical treatment of acutely and chronically obstructed coronary artery vessels. It is also the centerpiece for various new intervention techniques. Their morphologic effects on the site of obstru ... Full text Link to item Cite

Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures--Part V.

Journal article Clin Cardiol · January 1997 Catheter balloon angioplasty is a well accepted form of nonsurgical treatment of acutely and chronically obstructed coronary artery vessels. It is also the centerpiece for various new intervention techniques. Their morphologic effect on the site of obstruc ... Full text Link to item Cite

Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures--Part IV.

Journal article Clin Cardiol · December 1996 Catheter balloon angioplasty is a well accepted form of nonsurgical treatment of acutely and chronically obstructed coronary artery vessels. It is also the centerpiece for various new intervention techniques. Their morphologic effects on the site of obstru ... Full text Link to item Cite

Abrupt (< 1 day), acute (< 1 week), and early (< 1 month) vessel closure at the angioplasty site. Morphologic observations and causes of closure in 130 necropsy patients undergoing coronary angioplasty.

Journal article Clin Cardiol · November 1996 While abundant clinical and angiographic data are available regarding features of acute or abrupt closure at the site of balloon angioplasty, little morphologic information is available. This study discusses morphologic-histologic causes for acute closure ... Full text Link to item Cite

Coronary artery and saphenous vein graft remodeling: A review of histologic findings after various interventional procedures--Part III.

Journal article Clin Cardiol · November 1996 Catheter balloon angioplasty is a well accepted form of nonsurgical treatment of acutely and chronically obstructed coronary artery vessels. It is also the centerpiece for various new intervention techniques. Their morphologic effects on the site of obstru ... Full text Link to item Cite

Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures--Part I.

Journal article Clin Cardiol · September 1996 Catheter balloon angioplasty is a well accepted form of nonsurgical treatment of acutely and chronically obstructed coronary artery vessels. It is also the centerpiece for various new intervention techniques. Their morphologic effects on the site of obstru ... Full text Link to item Cite

Nonatherosclerotic causes of coronary artery narrowing--Part III.

Journal article Clin Cardiol · August 1996 Approximately 5% of patients with acute myocardial infarction do not have atherosclerotic coronary artery disease but have other causes for their luminal narrowing. The third part of this three-part review of nonatherosclerotic causes of coronary narrowing ... Full text Link to item Cite

Nonatherosclerotic causes of coronary artery narrowing--Part II.

Journal article Clin Cardiol · July 1996 Part II of this three-part article on nonatherosclerotic causes of coronary heart disease focuses on myocardial bridges, coronary artery aneurysms, emboli, coronary dissection, and spasm as causes of luminal narrowing. ... Full text Link to item Cite

Nonatherosclerotic causes of coronary artery narrowing--Part I.

Journal article Clin Cardiol · June 1996 Approximately 5% of patients with acute myocardial infarction do not have atherosclerotic coronary artery disease but have other causes for their luminal narrowing. The first part of this three-part review of nonatherosclerotic causes of coronary narrowing ... Full text Link to item Cite

Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty.

Journal article Cathet Cardiovasc Diagn · April 1996 Percutaneous coronary revascularization in patients with unstable angina and coronary thrombus carries a high complication rate. A new strategy to reduce thrombus burden before revascularization was tested in a multicenter prospective trial. Patients with ... Full text Link to item Cite

Late coronary artery stenosis regression within the Gianturco-Roubin intracoronary stent.

Journal article Am J Cardiol · February 1, 1996 The late angiographic outcome of the Gianturco-Roubin intracoronary stent has not been well defined. To investigate serial changes within the stent, we studied 23 patients (15 men and 8 women, median age 63) who had late angiographic follow-up ( > 1 year) ... Full text Link to item Cite

Coronary artery and saphenous vein graft remodeling: A review of histologic findings after various interventional procedures - Part II

Journal article Clinical Cardiology · January 1, 1996 Catheter balloon angioplasty is a well accepted form of nonsurgical treatment of acutely and chronically obstructed coronary artery vessels. It is also the centerpiece for various new intervention techniques. Their morphologic effects on the site of obstru ... Full text Cite

Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival.

Journal article J Am Coll Cardiol · November 15, 1995 OBJECTIVES: This study sought to determine the long-term outcome of adult patients undergoing percutaneous balloon aortic valvuloplasty. BACKGROUND: Percutaneous balloon aortic valvuloplasty has been offered as an alternative to aortic valve replacement fo ... Full text Link to item Cite

Indications for and applications of the Gianturco-Roubin coronary stent.

Journal article Cardiol Clin · November 1994 The Gianturco-Roubin coronary stent is approved for and effective in the management of acute or threatened closure after unsuccessful coronary intervention. Factors critical to successful stenting include patient and lesion selection, preprocedure identifi ... Link to item Cite

In vivo validation of compensatory enlargement of atherosclerotic coronary arteries.

Journal article Am J Cardiol · March 15, 1993 Necropsy examinations and epicardial ultrasound studies have suggested that atherosclerotic coronary arteries undergo compensatory enlargement. This increase in vessel size may be an important mechanism for maintaining myocardial blood flow. It also is of ... Full text Link to item Cite

Unrecognized left main coronary artery disease in patients undergoing interventional procedures.

Journal article Am J Cardiol · January 15, 1993 Selective, coronary arteriographic, catheter-based, intravascular ultrasound images were obtained to determine the presence and extent of angiographically undetected or underestimated left main (LM) coronary arterial narrowing in patients receiving coronar ... Full text Link to item Cite

Ergonovine maleate testing during cardiac catheterization: a 10-year perspective in 3,447 patients without significant coronary artery disease or Prinzmetal's variant angina.

Journal article J Am Coll Cardiol · July 1992 The utility of ergonovine testing for coronary artery spasm was assessed in 3,447 patients with angiographically insignificant (less than 50% diameter stenosis) or no coronary artery disease. No patients clinically had Prinzmetal's variant angina. Overall, ... Full text Link to item Cite

Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization.

Journal article J Am Soc Nephrol · May 1992 The purposes of this study were to determine the prevalence of angiographically significant renal artery stenosis in a patient population referred for diagnostic cardiac catheterization and to develop a model that predicts the highest-risk subset of patien ... Full text Link to item Cite

Use of balloon occlusion to improve visualization of anomalous pulmonary venous return in an adult with cor triatriatum.

Journal article Cathet Cardiovasc Diagn · April 1992 Cor triatriatum, although rare in adults, is often associated with anomalous pulmonary venous return. Accurate diagnosis of the pulmonary venous return and its anatomic connections is essential in planning proper surgical correction. This case illustrates ... Full text Link to item Cite

Quantitative and qualitative coronary angiographic analysis: review of methods, utility, and limitations.

Journal article Cathet Cardiovasc Diagn · February 1992 Coronary angiography continues to be the pivotal study in the diagnosis and treatment of ischemic cardiac disease. Although angiographic equipment and imaging techniques have advanced over the past three decades, the analysis of coronary angiograms, by vis ... Full text Link to item Cite

Left ventricular filling and ventricular diastolic performance after percutaneous balloon mitral valvotomy.

Journal article Am J Cardiol · January 1, 1992 The time course of left ventricular (LV) filling and LV diastolic performance were examined in 27 consecutive patients in sinus rhythm before and acutely after balloon mitral valvotomy (BMV). The mitral valve area acutely increased from 1.1 +/- 0.3 to 2.1 ... Full text Link to item Cite

Predictors of one-year outcome after balloon aortic valvuloplasty

Journal article Cardiology Board Review · January 1, 1992 Cite

Determinants of one-year outcome from balloon aortic valvuloplasty.

Journal article Am J Cardiol · July 1, 1991 Balloon aortic valvuloplasty (BAV) has been a therapeutic alternative treatment for severe symptomatic aortic stenosis. Previous studies have been unable to predict 1-year outcome because of limited acute and follow-up clinical, invasive and echocardiograp ... Full text Link to item Cite

Complications After Self-expanding Transcatheter or Surgical Aortic Valve Replacement.

Journal article Semin Thorac Cardiovasc Surg Procedural complications following transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) are usually reported as retrospective analyses. We report the first comparison of complications following SAVR or self-expanding TA ... Full text Link to item Cite